Printer Friendly

VIRATEK INC. LISTS ON THE AMERICAN STOCK EXCHANGE

 NEW YORK, Nov. 16 ~PRNewswire~ -- Viratek Inc. (AMEX: VRA) of Costa Mesa, Calif., commenced trading today on the American Stock Exchange. Trading under ticker symbol "VRA," the company's common stock, which previously traded over-the-counter on the NASDAQ System, opened at 12:15 p.m. Eastern Standard time on a quote of 3~8 (bid) to 5~8 (offer) at 1,000 shares. The company has chosen Kalb Voorhis & Co. as its specialist unit.
 Viratek Inc. is engaged in the development of pharmaceutical compounds derived from nucleic acids (DNA and RNA) and their building blocks as well as new biomedical products.
 The company's major focus has been on the development of therapeutically useful antiviral, anticancer and immune-modulating compounds. The company's current development efforts concentrate on the clinical testing of the antiviral Virazole in the treatment of chronic active hepatitis C.
 Virazole has received authorization for commercial sale and marketing in more than 40 countries, including the United States, Canada, Western Europe, Eastern Europe, Latin America and the Far East for a variety of viral infections. In the United States and 22 other countries it is authorized in aerosol form for the treatment of infants hospitalized with severe lower respiratory tract infection caused by respiratory syncytial virus.
 "We are pleased to be associated with the American Stock Exchange, particularly as this represents a new plateau in the maturity of our company and our pioneer role in the field of antivirals," said Robert A. Smith, Ph.D., president of Viratek Inc.
 For the nine months ended Sept. 30, 1992, Viratek Inc. reported a net income of $3 million or 21 cents per share, up from $2 million or 14 cents per share for the same period one year earlier.
 The American Stock Exchange is committed to becoming the recognized, premier marketplace for growth companies and derivative securities. By responding to listed company needs and initiating quality services, the Amex finds innovative ways to add value to the expanding community of companies and investors it serves.
 -0- 11~16~92
 ~CONTACT: Paul D. Nobile, manager, Equities Communications, 212-306-2028, for Viratek~
 (VRA)


CO: Viratek Inc. ST: California, New York IN: MTC SU:

LS -- LA033 -- 1388 11~16~92 15:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1992
Words:366
Previous Article:DALLAS GOLD AND SILVER EXCHANGE ANNOUNCES THIRD QUARTER AND NINE-MONTH RESULTS
Next Article:/C O R R E C T I O N -- VIRATEK INC. LISTS ON AMEX/
Topics:


Related Articles
ICN PHARMACEUTICALS NOT AWARE OF REASON FOR STOCK ACTIVITY
VIRATEK, INC., LISTS ON THE AMERICAN STOCK EXCHANGE
VIRATEK MAKES PUBLIC OFFERING
VIRATEK ANNOUNCES SEPARATION AND REDEMPTION OF WARRANTS
VIRATEK SUCCESSFULLY COMPLETES FINANCING: VIRATEK WARRANTS EXERCISED PROCEEDS EXCEED $14 MILLION
FORMER ICN EMPLOYEE DISCREDITS ICN'S CLAIMS AGAINST RAFI KAHN
COMMON STOCKS OF ICN PHARMACEUTICALS, THREE OPERATING UNITS, TOP MAJOR STOCK MARKET INDICES IN 1993
ICN PHARMACEUTICALS ISSUES STATEMENT ON RECENT MARKET ACTIVITY
VIRATEK DECLARES 5 PERCENT COMMON STOCK DIVIDEND
ICN WILL PAY THIRD AND FOURTH QUARTER DIVIDENDS IN DECEMBER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters